Phaseline

Companies › CSPC Ouyi Pharmaceutical

CSPC Ouyi Pharmaceutical: clinical trials, targets and expected readouts

5 active drug programs in 5 registered trials: 3 Phase 1, 2 Phase 3; Metabolic and endocrine, Other, Psychiatry; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Prusogliptin
Dipeptidyl peptidase-4 inhibitor
DPP4Phase 3Type 2 DiabetesNov 2026
Dextromethorphan
Sigma opioid receptor agonist; Glutamate [NMDA] receptor subunit epsilon 1 antagonist
SIGMAR1, GRIN2APhase 3Major Depressive Disorder (MDD)Dec 2026
SYH2069 Injection–Phase 1Overweight or ObesityNov 2026
SYH2082 Injection–Phase 1Overweight or ObesityDec 2026
SYH9089 injection–Phase 1Postoperative PainDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07026968PrusogliptinPhase 3Type 2 DiabetesMetabolic and endocrineNov 2026
NCT07736391SYH2069 InjectionPhase 1Overweight or ObesityMetabolic and endocrineNov 2026
NCT07736404SYH2082 InjectionPhase 1Overweight or ObesityMetabolic and endocrineDec 2026
NCT06958692DextromethorphanPhase 3Major Depressive Disorder (MDD)PsychiatryDec 2026
NCT07519109SYH9089 injectionPhase 1Postoperative PainOtherDec 2026

Targets

DPP4 (1) SIGMAR1 (1) GRIN2A (1)

Companies with the same targets

Exciva AstraZeneca Han Xu, M.D., Ph.D., FAPCR, Medical Director, IRB Chair Nabiqasim Industries (Pvt) JW Pharmaceutical UCB BIOSCIENCES Anavex Life Sciences Pentixapharm Zogenix Syndeio Biosciences

Companies built like this

Beijing QL Biopharmaceutical Gan & Lee Pharmaceuticals. BrightGene Bio-Medical Technology JCR Pharmaceuticals BioMarin Pharmaceutical

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.